Oz Management LP Has Lifted Its Position in Charles Riv Labs Intl INC (CRL) as Market Value Declined

Charles River Laboratories International, Inc. (NYSE:CRL) LogoInvestors sentiment increased to 1.06 in 2019 Q2. Its up 0.19, from 0.87 in 2019Q1. It is positive, as 31 investors sold CRL shares while 117 reduced holdings. 49 funds opened positions while 108 raised stakes. 45.51 million shares or 0.90% more from 45.11 million shares in 2019Q1 were reported. Primecap Mngmt Ca invested 0.04% in Charles River Laboratories International, Inc. (NYSE:CRL). Cambridge Advsr has 0.09% invested in Charles River Laboratories International, Inc. (NYSE:CRL) for 2,000 shares. 77 are held by Kings Point Capital Mngmt. Goldman Sachs Group owns 777,507 shares. Amer Group owns 95,642 shares or 0.05% of their US portfolio. Wells Fargo And Communications Mn holds 1.04 million shares. 125 are owned by Massmutual Trust Fsb Adv. Nebraska-based Farmers Merchants Invs Inc has invested 0% in Charles River Laboratories International, Inc. (NYSE:CRL). Keybank Association Oh reported 0% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL). Invest House Ltd Limited Liability Company reported 95,353 shares. Virginia Retirement Et Al owns 0.02% invested in Charles River Laboratories International, Inc. (NYSE:CRL) for 10,900 shares. Los Angeles Capital Mngmt And Equity Rech reported 68,941 shares. Moreover, Utah Retirement System has 0.02% invested in Charles River Laboratories International, Inc. (NYSE:CRL) for 9,079 shares. Principal Fin Grp Incorporated reported 217,538 shares. Pembroke Ltd holds 1.55% or 103,351 shares in its portfolio.

Oz Management Lp increased its stake in Charles Riv Labs Intl Inc (CRL) by 25.47% based on its latest 2019Q2 regulatory filing with the SEC. Oz Management Lp bought 77,700 shares as the company’s stock declined 2.05% . The hedge fund held 382,746 shares of the health care company at the end of 2019Q2, valued at $54.31 million, up from 305,046 at the end of the previous reported quarter. Oz Management Lp who had been investing in Charles Riv Labs Intl Inc for a number of months, seems to be bullish on the $6.52B market cap company. The stock increased 0.35% or $0.46 during the last trading session, reaching $132.25. About 496,775 shares traded or 51.18% up from the average. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 11.21% since September 13, 2018 and is uptrending. It has outperformed by 11.21% the S&P500.

Oz Management Lp, which manages about $56.28 billion and $18.76B US Long portfolio, decreased its stake in Lowes Cos Inc (NYSE:LOW) by 957,241 shares to 1.42M shares, valued at $143.43 million in 2019Q2, according to the filing. It also reduced its holding in Workday Inc (Prn) by 14.00 million shares in the quarter, leaving it with 21.90 million shares, and cut its stake in Crown Castle Intl Corp New.

More notable recent Charles River Laboratories International, Inc. (NYSE:CRL) news were published by: Businesswire.com which released: “Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform – Business Wire” on October 25, 2018, also Benzinga.com with their article: “Earnings Scheduled For May 7, 2019 – Benzinga” published on May 07, 2019, Seekingalpha.com published: “Charles River Laboratories (CRL) To Present At 37th Annual J.P. Morgan Healthcare Conference – Slideshow – Seeking Alpha” on January 09, 2019. More interesting news about Charles River Laboratories International, Inc. (NYSE:CRL) were released by: Fool.com and their article: “Is iShares Nasdaq Biotechnology Index Fund a Buy? – Motley Fool” published on March 11, 2019 as well as Seekingalpha.com‘s news article titled: “Charles River Laboratories beats by $0.01, beats on revenue – Seeking Alpha” with publication date: May 07, 2019.

Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Coverage

Among 2 analysts covering Charles River Labs (NYSE:CRL), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Charles River Labs has $170 highest and $145 lowest target. $157.50’s average target is 19.09% above currents $132.25 stock price. Charles River Labs had 4 analyst reports since March 14, 2019 according to SRatingsIntel. On Monday, March 18 the stock rating was maintained by Barclays Capital with “Hold”. Argus Research maintained the shares of CRL in report on Thursday, March 14 with “Buy” rating.

Charles River Laboratories International, Inc. (NYSE:CRL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.